EconomyGSK shares dive as weaker sales and rising costs unsettle investors

GSK shares fell as much as 7% on Wednesday, later narrowing the loss to 5.5%, despite better-than-expected results. The British drugmaker’s third-quarter pre-tax profit fell 19% to £1.9bn, while vaccine sales declined and restructuring charges reached £318m. Investors are also concerned about the approaching patent loss for its blockbuster HIV drug.

GSKpharmaceuticalscompany resultsshares

TThe Guardian★★☆☆☆2026-10-28 12:44Original